Terra Alpha Investments LLC Buys New Shares in IQVIA Holdings Inc. (NYSE:IQV)

Terra Alpha Investments LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 7,297 shares of the medical research company's stock, valued at approximately $1,434,000. IQVIA makes up about 1.5% of Terra Alpha Investments LLC's investment portfolio, making the stock its 28th biggest position.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $33,000. Avior Wealth Management LLC grew its holdings in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares in the last quarter. Assetmark Inc. increased its position in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after purchasing an additional 196 shares during the last quarter. Meeder Asset Management Inc. raised its stake in shares of IQVIA by 353.7% in the 3rd quarter. Meeder Asset Management Inc. now owns 245 shares of the medical research company's stock valued at $58,000 after purchasing an additional 191 shares in the last quarter. Finally, Versant Capital Management Inc lifted its position in shares of IQVIA by 46.0% during the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock worth $58,000 after purchasing an additional 93 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

IQVIA Price Performance

IQVIA stock traded up $1.59 during trading hours on Friday, hitting $185.85. 3,242,588 shares of the company traded hands, compared to its average volume of 1,237,538. The firm's 50-day simple moving average is $195.30 and its two-hundred day simple moving average is $209.18. The firm has a market cap of $32.77 billion, a P/E ratio of 24.78, a P/E/G ratio of 1.99 and a beta of 1.50. IQVIA Holdings Inc. has a 1-year low of $179.28 and a 1-year high of $256.29. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts have issued reports on IQV shares. Bank of America cut their price objective on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. William Blair reissued an "outperform" rating on shares of IQVIA in a research report on Wednesday, December 11th. BTIG Research downgraded shares of IQVIA from a "buy" rating to a "neutral" rating in a report on Monday, February 3rd. Robert W. Baird dropped their target price on shares of IQVIA from $212.00 to $210.00 and set a "neutral" rating on the stock in a report on Tuesday, January 21st. Finally, Morgan Stanley lifted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a report on Tuesday, February 11th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and an average price target of $249.05.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.